Patents by Inventor Byeong Chang

Byeong Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10799589
    Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 13, 2020
    Assignee: BUZZARD PHARMACEUTICALS AB
    Inventors: Gregory Zarbis-Papastoitsis, Patricia Lowden, Byeong Chang
  • Publication number: 20200129610
    Abstract: This disclosure provides a novel lyophilized formulation that incorporates a surfactant solution to stabilize the Sabin inactivated polio vaccine and demonstrate the vaccine efficacy in an in vivo challenge model. Furthermore, SE-HPLC analysis of D-antigen content in in inactivated polio vaccine can be used to provide a method for high throughput evaluation of inactivated poliovirus stability.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 30, 2020
    Inventors: Jae Jung, Daiki Hara, Byeong Chang, Francisca Gbormittah, Michael Reilly, Woo-Jin Shin
  • Publication number: 20180177877
    Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 28, 2018
    Inventors: Gregory Zarbis-Papastoitsis, Patricia Lowden, Byeong Chang
  • Publication number: 20140308239
    Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 16, 2014
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Gregory Zarbis-Papastoitsis, Patricia Lowden, Byeong Chang
  • Patent number: 8785168
    Abstract: The present invention provides improved formulations for lysosomal enzymes useful for enzyme replacement therapy. Among other things, the present invention provides formulations that preserve or enhance the stability and/or efficacy of a lysosomal enzyme such as acid alpha-glucosidase.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: July 22, 2014
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Jonathan LeBowitz, Byeong Chang
  • Publication number: 20120148556
    Abstract: The present invention provides improved formulations for lysosomal enzymes useful for enzyme replacement therapy. Among other things, the present invention provides formulations that preserve or enhance the stability and/or efficacy of a lysosomal enzyme such as acid alpha-glucosidase.
    Type: Application
    Filed: June 17, 2010
    Publication date: June 14, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Jonathan LeBowitz, Byeong Chang
  • Patent number: 7879805
    Abstract: A stabilized pharmaceutical composition in the form of a lyophilized product to be later reconstituted to generate an aqueous drug product is described herein. The therapeutically active ingredient in the form of a peptide of sequence TDLQERGDNDISPFSGDGQPFKD is stabilized with a buffer, carbohydrate stabilizer, a nonionic bulking agent and a surfactant to facilitate reconstitution. The preferred preparation contains a peptide of the sequence TDLQERGDNDISPFSGDGQPFKD, histidine buffer, mannitol or glycine, sucrose and/or Polysorbate 20. This combination of excipients has demonstrated exceptional stability as a lyophilized product when stored at the elevated temperature of 40° C. for at least 6 months and for at least 3 Months at 50° C. The lyophilized mixture thus formed is reconstituted to a high peptide concentration without apparent loss of stability of the peptide.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: February 1, 2011
    Assignee: Acologix, Inc.
    Inventors: Dennis Chen, Russell Wayne Blacher, Byeong Chang
  • Publication number: 20100197751
    Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
    Type: Application
    Filed: April 29, 2009
    Publication date: August 5, 2010
    Inventors: Bruce Kerwin, Byeong Chang, Lei Shi
  • Patent number: 7700722
    Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: April 20, 2010
    Assignee: Amgen Inc.
    Inventors: Bruce Kerwin, Byeong Chang, Lei Shi
  • Publication number: 20090054331
    Abstract: A stabilized pharmaceutical composition in the form of a lyophilized product to be later reconstituted to generate an aqueous drug product is described herein. The therapeutically active ingredient in the form of a peptide of sequence TDLQERGDNDISPFSGDGQPFKD is stabilized with a buffer, carbohydrate stabilizer, a nonionic bulking agent and a surfactant to facilitate reconstitution. The preferred preparation contains a peptide of the sequence TDLQERGDNDISPFSGDGQPFKD, histidine buffer, mannitol or glycine, sucrose and/or Polysorbate 20. This combination of excipients has demonstrated exceptional stability as a lyophilized product when stored at the elevated temperature of 40° C. for at least 6 months and for at least 3 Months at 50° C. The lyophilized mixture thus formed is reconstituted to a high peptide concentration without apparent loss of stability of the peptide.
    Type: Application
    Filed: May 29, 2008
    Publication date: February 26, 2009
    Inventors: Dennis CHEN, Russell Wayne BLACHER, Byeong CHANG
  • Publication number: 20080249017
    Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GHRH molecules as active ingredient, and more particularly GHRH analogs including [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises an anionic surfactant and a non-reducing sugar, and has a pH of about 4.0 to about 7.5. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it.
    Type: Application
    Filed: April 4, 2008
    Publication date: October 9, 2008
    Applicant: THERATECHNOLOGIES INC.
    Inventors: Helen Loughrey, Byeong Chang
  • Publication number: 20070225640
    Abstract: A container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products is disclosed. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step.
    Type: Application
    Filed: March 9, 2007
    Publication date: September 27, 2007
    Inventors: Byeong Chang, Roger Liu
  • Publication number: 20060157507
    Abstract: A container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products is disclosed. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step. Importantly, the container closure assembly also provides for modularity of dosing, the ability to dose multiple products in a single dose, intranasal delivery, and multi-dosing.
    Type: Application
    Filed: March 20, 2006
    Publication date: July 20, 2006
    Inventors: Byeong Chang, Roger Liu
  • Publication number: 20060144869
    Abstract: The present invention relates to a container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step.
    Type: Application
    Filed: June 30, 2005
    Publication date: July 6, 2006
    Inventors: Byeong Chang, Roger Liu
  • Publication number: 20060119485
    Abstract: A computer having a speaker outputting a sound, the computer including: a sound signal output unit outputting a speaker sound signal to the speaker; a speaker output control unit controlling whether the sound signal output unit to output the speaker sound signal; and an alarm control unit controlling the speaker output control unit so that the sound signal output unit outputs the speaker sound signal when a predetermined alarm condition is detected, and the sound signal output unit so that the speaker generates a preset alarm sound to correspond to the alarm condition.
    Type: Application
    Filed: November 2, 2005
    Publication date: June 8, 2006
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Byeong-chang Lee, Seung-loon Park
  • Patent number: 6983053
    Abstract: A computing device allows selective output of audio signals within a frequency band. The computing device has a main system having an audio signal generator generating audio signals, a main audio outputting unit attached to the main system and outputting the generated audio signals, an auxiliary system connected to the main system and receiving the audio signals generated by the audio signal generating unit, and an auxiliary audio outputting unit attached to the auxiliary system and outputting the audio signals received in the auxiliary system A switching unit controls the audio signals to pass through a plurality of selectable filters filtering the audio signals within respective frequency bands and to supply the selected filtered audio signals to the main audio outputting unit, and to the auxiliary audio outputting unit, depending upon whether the auxiliary system is connected to the main system.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: January 3, 2006
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Byeong-chang Lee, In-don Ju
  • Publication number: 20040122543
    Abstract: A computing device allows selective output of audio signals within a frequency band. The computing device has a main system having an audio signal generator generating audio signals, a main audio outputting unit attached to the main system and outputting the generated audio signals, an auxiliary system connected to the main system and receiving the audio signals generated by the audio signal generating unit, and an auxiliary audio outputting unit attached to the auxiliary system and outputting the audio signals received in the auxiliary system A switching unit controls the audio signals to pass through a plurality of selectable filters filtering the audio signals within respective frequency bands and to supply the selected filtered audio signals to the main audio outputting unit, and to the auxiliary audio outputting unit, depending upon whether the auxiliary system is connected to the main system.
    Type: Application
    Filed: June 24, 2003
    Publication date: June 24, 2004
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Byeong-Chang Lee, In-Don Ju
  • Publication number: 20040002451
    Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
    Type: Application
    Filed: June 20, 2002
    Publication date: January 1, 2004
    Inventors: Bruce Kerwin, Byeong Chang, Lei Shi
  • Publication number: 20030236196
    Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
    Type: Application
    Filed: June 12, 2003
    Publication date: December 25, 2003
    Applicant: Amgen Inc.
    Inventors: Bruce Kerwin, Byeong Chang, Lei Shi
  • Publication number: 20030104996
    Abstract: The present invention relates to single use and multi-dose pharmaceutical formulations comprising a biologically active agent and methionine, wherein said formulations demonstrate improved stability, and wherein said formulations do not contain human serum albumin.
    Type: Application
    Filed: August 30, 2001
    Publication date: June 5, 2003
    Inventors: Tiansheng Li, Byeong Chang, Christopher Sloey